Three years ago, anyone not living with type-2 diabetes or working in medicine would hardly have heard of the hormone GLP-1.
Today, it’s everywhere. From public policy documents and clinical trials to social media and celebrity-led commercials, GLP-1 injections, better known by brand names Ozempic, Wegovy and Mounjaro, have infiltrated every corner of society. They’re discussed at dinner tables, debated online and, most recently, reflected on supermarket shelves, after both Morrisons and Marks & Spencer released ranges of high-protein, smaller-portion meals designed for reduced appetites.
